The National Agency for Food and Drug Administration and Control (NAFDAC) has destroyed expired donated medicines valued at ₦59 million at the Igwuruta dump site in Port Harcourt, Rivers State.

The medicines were brought into Nigeria from the United States through the Nigeria Ports Authority (NPA) Area 1 Port in Port Harcourt. The consignment included antidepressants, anti-ulcer medicines, analgesics and medicines used in the management of hypertension.

The products were identified as expired and were subsequently removed from the pharmaceutical supply chain for safe destruction. The available information does not establish when the medicines expired, so it is not clear from the report whether they had expired before arrival in Nigeria or during the period they remained under regulatory control.

Importantly, there is no indication in the information provided by NAFDAC that the medicines were distributed to patients or healthcare facilities before the regulatory action. The destruction therefore ensured that the products did not proceed further into circulation.

Donated medicines can play an important role in supporting healthcare delivery, particularly for vulnerable and underserved populations. However, their safety and suitability for use remain essential considerations throughout the pharmaceutical supply chain.

Medicines that have expired or are otherwise unsuitable for use should not be supplied to patients. Removing such products from circulation and destroying them through appropriate procedures helps reduce the risk of misuse, diversion or unauthorised distribution.

The destruction exercise was conducted in collaboration with the Nigeria Customs Service and other sister agencies, highlighting the role of inter-agency cooperation in monitoring pharmaceutical products entering the country and protecting the integrity of the medicine supply chain.

For pharmacists and other professionals involved in medicine procurement, donations and distribution, the incident also underscores the importance of appropriate regulatory oversight of donated pharmaceutical products from the point of entry through to their intended use.

The case reinforces a basic principle of pharmaceutical supply-chain management: medicines intended to support healthcare delivery must remain within appropriate quality, safety and regulatory requirements before reaching patients.